It’s not about pharmaceuticals, it’s about people
At AbelaPharm, we strive to meet and exceed our customer’s needs.
Through our innovative research and production methods, we are able to deliver incomparable levels of quality products. Our main objective is to provide our customers with the highest grade of completely natural and licensed dietary supplements, catering to a multitude of needs.
The trademark that AbelaPharm products bear, represents our commitment to the constant research and development of safe products.
Our aim is to become the first choice to as many customers as possible through our innovative practices, and in turn, establish a dominant presence within the pharmaceutical industry – both locally and globally.
Quality comes first
The main goal of the company Abela Pharm is to place efficient, high-quality and safe products on the market. Therefore, the company has set very clear demands which are met by all the employees.
Production
Solid pharmaceutical forms and solutions are produced at the Abela Pharm plant. The capacity of the production equipment is compliance with the operating demands.
Innovation
The goal of the company Abela Pharm is to establish good long-term business relations with its partners and to ensure the availability of the unique pharmaceutical products in the market.
AbelaPharm Swiss producer has bought the production facility from German company STADA
AbelaPharm Swiss producer, one of the leaders in the field of probiotic production in the Balkans, has officially acquired the production facility from German pharmaceutical company STADA in a nearby surrounding of Belgrade.
This is the second factory owned by AbelaPharm, where more than 6 million euros have been invested over the last year and a half in the equipment, machinery, plants, production processes and manufacturing licenses acquired from prominent European and global companies.
AbelaPharm Swiss producer has acquired the factory of American company Alvogen
Alvogen and AbelaPharm Swiss have announced today that they have signed a purchase agreement and officially conducted the handover of the factory in Serbia.
A state-of-the-art facility with the highest GMP standards provides a prerequisite for the production of 20 million pharmaceutical units annually, built by the Alvogen in 2011.
‘’Taking over the third factory is a significant step to the achievement of our goals. It enables the specialization of the existing plants and strong development of our portfolio with increasing market share in the fields of gastroenterology, cardiology, pulmonology, and rheumatology.